Business Context and Reporting Period
Company: VistaGen Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 27, 2017
Event: Announcement of the peer-reviewed publication of nonclinical studies regarding the Company's central nervous system (CNS) prodrug candidate, AV-101 (4-Cl-KYN).
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding a scientific publication and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes are reported in this document. The material event is the publication of the study titled "Characterization of the effects of L-4-chlorokynurenine on nociception in rodents" in The Journal of Pain. The study evaluates the effects of AV-101 in four well-established nonclinical models of pain.
Outlook, Commentary, and Risks
- Management Commentary: The publication was led by Tony L. Yaksh, Ph.D. (UCSD), Robert Schwarcz, Ph.D. (University of Maryland), and H. Ralph Snodgrass, Ph.D. (VistaGen President and CSO).
- Unusual Items: None reported.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study results.
- Review the peer-reviewed article in The Journal of Pain (DOI: 10.1016/j.jpain.2017.03.014) to assess the clinical relevance of the nonclinical data.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial impacts or updates on the AV-101 development timeline.